 Connection
Edward Ashwood to Prenatal Diagnosis
This is a "connection" page, showing publications Edward Ashwood has written about Prenatal Diagnosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.420 |
|
|
|
-
Ashwood ER, Palomaki GE. A new era in noninvasive prenatal testing. N Engl J Med. 2013 11 28; 369(22):2164.
Score: 0.397
-
Walker BS, Nelson RE, Jackson BR, Grenache DG, Ashwood ER, Schmidt RL. A Cost-Effectiveness Analysis of First Trimester Non-Invasive Prenatal Screening for Fetal Trisomies in the United States. PLoS One. 2015; 10(7):e0131402.
Score: 0.111
-
Walker BS, Jackson BR, LaGrave D, Ashwood ER, Schmidt RL. A cost-effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndrome. Prenat Diagn. 2015 May; 35(5):440-6.
Score: 0.110
-
Palomaki GE, Ashwood ER, Best RG, Lambert-Messerlian G, Knight GJ. Is maternal plasma DNA testing impacting serum-based screening for aneuploidy in the United States? Genet Med. 2015 Nov; 17(11):897-900.
Score: 0.109
-
Palomaki GE, Ashwood ER, Weck KE. A flawed challenge but valid recommendation: a response to Takoudes and Hamar. Ultrasound Obstet Gynecol. 2015 Jan; 45(1):117.
Score: 0.107
-
Walker B, Ashwood ER, Jackson BR, Lagrave D. A tradeoff analysis of risk cutoffs for the quadruple serum screen for Down syndrome. Prenat Diagn. 2013 Dec; 33(12):1201-6.
Score: 0.098
-
Palomaki GE, Knight GJ, Ashwood ER, Best RG, Haddow JE. Screening for down syndrome in the United States: results of surveys in 2011 and 2012. Arch Pathol Lab Med. 2013 Jul; 137(7):921-6.
Score: 0.097
-
Ashwood ER, Palmer SE, Lenke RR. Rapid fetal lung maturity testing: commercial versus NBD-phosphatidylcholine assay. Obstet Gynecol. 1992 Dec; 80(6):1048-53.
Score: 0.093
-
Ashwood ER. Evaluating health and maturation of the unborn: the role of the clinical laboratory. Clin Chem. 1992 Aug; 38(8B Pt 2):1523-9.
Score: 0.091
-
Ashwood ER, Cheng E, Luthy DA. Maternal serum alpha-fetoprotein and fetal trisomy-21 in women 35 years and older: implications for alpha-fetoprotein screening programs. Am J Med Genet. 1987 Mar; 26(3):531-9.
Score: 0.062
-
Erickson JA, Ashwood ER, Gin CA. Evaluation of a dimeric inhibin-A assay for assessing fetal Down syndrome: establishment, comparison, and monitoring of median concentrations for normal pregnancies. Arch Pathol Lab Med. 2004 Apr; 128(4):415-20.
Score: 0.051
-
Lepage N, Wyatt P, Ashwood ER, Best RG, Long T, Palomaki GE. Prenatal serum screening for Down syndrome and neural tube defects in the United States: Changes in utilization patterns from 2012 to 2020. J Med Screen. 2021 12; 28(4):405-410.
Score: 0.042
-
Palomaki GE, Wyatt P, Best RG, Lepage N, Ashwood ER, Souers RJ, Thorson JA. Assessment of laboratories offering cell-free (cf) DNA screening for Down syndrome: results of the 2018 College of American Pathology External Educational Exercises. Genet Med. 2020 04; 22(4):777-784.
Score: 0.038
-
Ashwood ER, Tait JF, Foerder CA, Franklin RW, Benedetti TJ. Improved fluorescence polarization assay for use in evaluating fetal lung maturity. III. Retrospective clinical evaluation and comparison with the lecithin/sphingomyelin ratio. Clin Chem. 1986 Feb; 32(2):260-4.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|